Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evaxion A/S - American Depositary Share (NQ:EVAX)

5.890 +0.280 (+4.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evaxion A/S - American Depositary Share

< Previous 1 2 3 4 5 6 7 8 Next >
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
From Evaxion Biotech
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Are Evaxion Biotech Shares Trading Higher Today
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Mallinckrodt Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
Gainers Forza X1, Inc. (NASDAQ: FRZA) shares rose 85.6% to $2.32 in pre-market trading after the company tweeted Friday 'Get ready for something extraordinary! Stay tuned!' 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week off right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
From Evaxion Biotech
Via GlobeNewswire
Evaxion Announces Business Update and First Quarter 2023 Financial Results
From Evaxion Biotech
Via GlobeNewswire
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
From Evaxion Biotech
Via GlobeNewswire
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
From Evaxion Biotech
Via GlobeNewswire
Evaxion to host R&D Day on May 25, 2023
From Evaxion Biotech
Via GlobeNewswire
Fourth quarter and full year 2022 financial results and business update
From Evaxion Biotech
Via GlobeNewswire
Evaxion Biotech Says Personalized Cancer Immunotherapy Meets Primary Endpoint In Melanoma Patients
 
Via Benzinga
Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints
From Evaxion Biotech
Via GlobeNewswire
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional... 
Via Benzinga
Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform
From Evaxion Biotech
Via GlobeNewswire
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
From Evaxion Biotech
Via GlobeNewswire
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
From Evaxion Biotech
Via GlobeNewswire
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
From Evaxion Biotech
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 36 companies set new 52-week lows. 
Via Benzinga
Evaxion Biotech, Pantherna Reveals Encouraging Data From mRNA-Based Cancer Vaccine
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Our coverage starts today with a look at the biggest pre-market stock movers traders will want to keep an eye on Wednesday! 
Via InvestorPlace
Evaxion and Pantherna announce promising preclinical mRNA vaccine data
From Evaxion Biotech
Via GlobeNewswire
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
From Evaxion Biotech
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
From Evaxion Biotech
Via GlobeNewswire
Why Dermata Therapeutics Shares Are Trading Higher By Over 100%; Here Are 21 Stocks Moving Premarket
Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares rose 105% to $0.41 in pre-market trading after the company requested to withdraw its registration on Form S-1 and said it does not intend to... 
Via Benzinga
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
From Evaxion Biotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.